Alerta

ＣＴＭ標的指向化による敗血症性胆汁うっ滞の治療のためのＰＫＣ阻害剤

Resumen de: US2025268913A1

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.

脂質ナノ粒子の凍結乾燥方法及び組成物

Resumen de: CN120390635A

The present invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent; and a preparation method thereof.

阻害性核酸およびその使用方法

Resumen de: CN120603949A

The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of treating cancer using the inhibitory nucleic acids.

インフルエンザおよびＲＳＶに対する免疫原性組成物

Resumen de: TW202430642A

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

ＳＦＴＳウイルスワクチン

Resumen de: CN120583941A

Provided herein are compositions, systems, kits and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) with a composition i) comprising a plurality of nanoparticles self-assembled by a plurality of fusion proteins comprising a) at least a portion of a ferritin and b) an immunogenic protein, in some embodiments, the fusion protein comprises i) an immunogenic protein comprising at least a portion of an SFTS virus Gn and/or Gc envelope glycoprotein, or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

インフルエンザウイルス様粒子をコードするｍＲＮＡ

Resumen de: AU2023394992A1

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.

叶酸修饰的NK细胞来源的外泌体包载溶瘤呼肠孤病毒复合物及其制备方法和应用

Resumen de: CN121265553A

本发明公开了叶酸修饰的NK细胞来源的外泌体包载溶瘤呼肠孤病毒复合物及其制备方法和应用。所述复合物中叶酸与NKexo磷脂双分子层通过自组装插入的方式修饰NKexo；所述复合物中通过挤压法将Reo装载到NKexo中。所述方法包括步骤：提取NKexo，叶酸修饰NKexo，和叶酸修饰的NKexo包载Reo。本发明的叶酸修饰的NKexo包载Reo即能依靠NKexo自身的抗肿瘤特性能成为较好的运送载体，又能够通过叶酸与肿瘤中高表达的叶酸受体结合，从而保护并递送更多的Reo到达肿瘤部位，协同联合靶向治疗癌症。

ＲＳＶ感染によって引き起こされる疾患又は障害を予防する方法

Resumen de: US2022133875A1

The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth.

ポリサルコシンを含むＲＮＡ粒子

Resumen de: US2025367320A1

The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.

用于治疗免疫应答失调的基于微小RNA的颗粒

Resumen de: AU2024207086A1

A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.

一种脂质纳米颗粒的制备及其在膀胱灌注药物中的应用

Resumen de: CN121265556A

本发明提供了一种脂质纳米颗粒的制备及其在膀胱灌注药物中的应用，属于生物医药技术领域。本发明脂质纳米颗粒由离子型脂质、胆固醇、两亲性脂质和DOPE‑LA组成；所述离子型脂质为阳离子脂质或可电离脂质，该脂质纳米颗粒（LANP）表面具有二硫戊环结构，能够与细胞表面的巯基发生巯基‑二巯基交换反应，将LANP以化学键的形式黏附在膀胱内壁的黏膜上，以抵抗尿液外排导致的药物有效浓度降低。

一种可屏蔽NETs的神经营养因子纳米递送系统及其应用

Resumen de: CN121265756A

本发明涉及一种可屏蔽NETs的神经营养因子纳米递送系统及其应用，属于生物医药技术领域。本发明通过ATP对荷正电的BDNF进行可逆修饰得到荷负电的A‑BDNF；通过LPS处理小胶质细胞得到高表达聚唾液酸的小胶质细胞膜，使用PBM包被A‑BDNF得到A‑BDNF@PBM NPs。本发明的A‑BDNF@PBM NPs可有效富集于受损脊髓部位，并通过PBM表面高表达的聚唾液酸与NETs结合，触发PBM脱落，使位于PBM胞质小叶的PS暴露在NETs表面，PS充当“吃我”信号，使吞噬细胞通过胞葬作用清除NETs，引发神经保护性免疫反应。同时，释放的A‑BDNF在微酸性环境下恢复为BDNF，促进神经再生。

一种靶向肝实质细胞的核酸递送载体及其应用

Resumen de: CN121265551A

本发明涉及局部递送药物的材料及其应用。具体提供一种纳米颗粒组合物，所述纳米颗粒组合物包括阳离子脂质、PEG脂质和结构脂质；其中，PEG脂质的脂质组分为1.0‑5.5摩尔％，或上述任意两个数值之间的范围。本发明纳米颗粒组合物仅在施用部位递送。

两亲性嵌段聚合物、载药纳米颗粒粉末、载药水凝胶及制备方法和应用

Resumen de: CN121270779A

本发明公开了两亲性嵌段聚合物、载药纳米颗粒粉末、载药水凝胶及制备方法和应用，涉及骨损伤修复药物技术领域。两亲性嵌段聚合物的制备方法为：4‑二甲氨基苯酚与2‑溴异丁烯酰溴混合反应，得到引发剂P1；N‑叔丁羰基乙醇胺与甲基丙烯酰氯混合反应，得到单体Boc‑AEMA；1‑甲基‑2‑羟甲基咪唑与甲基丙烯酰氯混合反应，得到单体MPID；引发剂P1与单体Boc‑AEMA、单体MPID混合反应，得到聚合物BMP1；聚合物BMP1与三氟乙酸混合反应，得到两亲性嵌段聚合物BMP2。本发明通过设计含阳离子咪唑基团MPID与疏水脱保护胺基Boc‑AEMA的两亲性嵌段聚合物BMP2，突破传统凝胶需添加化学交联剂的局限，通过静电自交联触发原位凝胶化，规避外源交联剂导致的细胞毒性，且凝胶强度可通过聚合物浓度精准调控。

一种靶向性的药物递送载体及其制备方法

Resumen de: CN120242044A

The invention belongs to the technical field of biological medicine, and relates to a targeting drug delivery carrier and a preparation method thereof. The invention provides a targeting drug delivery carrier. The targeting drug delivery carrier comprises a drug carrier and targeting polypeptide, the drug carrier is a virus carrier, and the nucleotide of the targeting polypeptide is operably connected with the nucleotide of the capsid protein of the virus carrier; or the drug carrier is a non-viral carrier, the targeting polypeptide is connected with the non-viral carrier in a surface modification mode, and the amino acid sequence of the targeting polypeptide is shown as any one of SEQ ID NO: 8-12 and SEQ ID NO: 14. The efficient drug delivery carrier is designed and prepared by utilizing targeting polypeptide for specifically recognizing biomolecules, cells, tissues or organs.

一种用于局部给药的脂质纳米颗粒、其制备方法及其在制备抗疤痕药物上的应用

Resumen de: CN121265557A

本发明属于生物医药领域，具体涉及一种用于局部给药的脂质纳米颗粒、其制备方法及其在制备抗疤痕药物上的应用。本发明的脂质纳米颗粒，包含脂质载体以及由所述脂质载体所包裹的核酸，所述脂质载体包含以下成分：可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物；所述可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物的摩尔比为：25‑45：5‑25：1‑2：5‑15：35‑40。本发明针对现有技术存在的脂质纳米颗粒给药单一性的问题，将脂质纳米颗粒通过比例调控，设计成外用涂抹局部给药，提高靶向性、可给药浓度。避免全身血液循环，降低毒副作用、脱靶性。从而达到“增效”与“减毒”的双重目的。

一种负载核苷类似物的递送系统及其制备方法和应用

Resumen de: CN121265559A

本发明提供了一种负载核苷类似物的递送系统及其制备方法和应用，涉及医药技术领域。本发明中通过膜工程改造首次采用血小板膜与MSC细胞外泌体杂化获得的包裹材料负载吉西他滨，获得了高包封率、高载药量的吉西他滨递送系统，并且该系统具有优异的稳定性；该负载吉西他滨的血小板膜药物递送系统能够有效提高吉西他滨的胰腺癌治疗效果，为胰腺癌治疗提供了一种新的功能性药物形式。

一种用于mRNA递送的二硒键交联聚乙烯亚胺载体及其制备方法和用途

Resumen de: CN121270966A

本发明公开了一种用于mRNA递送的二硒键交联聚乙烯亚胺载体及其制备方法和用途，所述载体的制备是以合成的二硒‑1,6‑己二醇二丙烯酸酯单体(DSeDA)作为二硒交联剂，与分子量为0.6kDa/1.8kDa的分支PEI通过胺‑丙烯酸酯的Michael加成反应制备二硒交联的聚合物材料，且对未交联的伯胺进行疏水/亲水链的修饰，所述亲/疏水链为化合物CH2COO‑R，取代基R为C8‑C12直链烷基或聚乙二醇的6‑12寡聚体中的一种或几种。本发明载体结构中，交联剂引入可生物降解的二丙烯酸酯键和二硒键，在保持转染效率的同时最大限度地降低毒性。由于二硒键可同时对氧化和还原环境作出灵敏的响应，含二硒键聚合物分子可以成为一类新型的mRNA载体材料，在提高胞内mRNA释放和翻译方面可发挥促进作用。

一种pH响应性纳米药物递送系统及其制备方法与应用

Resumen de: CN121265813A

本发明属于生物医药技术领域，具体涉及一种pH响应性纳米药物递送系统及其制备方法与应用。所述pH响应性纳米药物递送系统由羧基化修饰的介孔硅基纳米载体、羧基活化剂和壳聚糖制得；该药物递送系统的制备方法包括提供介孔硅基载体、进行羧基化修饰和壳聚糖接枝三个步骤。本发明通过壳聚糖层实现对肿瘤酸性微环境的响应、以及靶向释放药物，可提高药物的疗效并降低毒副作用，该药物递送系统制备工艺简单、成本低廉、生物相容性好且载药量高。

霉酚酸前药分子的纳米颗粒及其治疗用途

Resumen de: AU2024255212A1

A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.

一种负载银纳米粒的脂质体纳米制剂及其制备和应用

Resumen de: CN121265552A

本发明属于医药技术领域，公开一种负载银纳米粒的脂质体纳米制剂及其制备和应用。本发明采用薄膜分散法制得包载银纳米粒的纳米颗粒。本发明的仿生纳米药物有助于解决抗菌药物银纳米粒细菌摄取效率低的问题，提高药物杀灭瘤内菌的能力，进而提高抗肿瘤效果。制备工艺简单、成本低、稳定性好、可重复性高。

一种条件激活型免疫细胞及其组合物和应用

Resumen de: CN121271804A

本发明涉及一种条件激活型免疫细胞及其组合物和应用。具体地，本发明提供一种偶联纳米颗粒的免疫细胞，免疫细胞表达嵌合抗原受体，所述免疫细胞通过连接子与纳米颗粒偶联，其中，所述连接子包含第一肽段，所述第一肽段包含一个或多个配体诱导型蛋白酶水解裂解位点。本发明提供一种定点“开关型”表达嵌合抗原受体的免疫细胞，能够实现对免疫细胞的精准调控，可有效降低靶向脱瘤毒性，进而降低毒副作用，极大地提高了安全性。

一种巴利森苷修饰的硒纳米颗粒及其制备方法和应用

Resumen de: CN121265555A

本发明属于硒纳米颗粒复合材料技术领域，具体涉及一种巴利森苷修饰的硒纳米颗粒及其制备方法和应用。本发明提供的巴利森苷修饰的硒纳米颗粒，具有核壳结构，包括硒纳米颗粒和包覆在硒纳米颗粒表面的巴利森苷。所述巴利森苷修饰的硒纳米颗粒中巴利森苷分子对葡萄糖转运蛋白‑1具有亲和力，表现出良好的靶向潜力，并具有良好的抗氧化效果。超小剂量的巴利森苷修饰的硒纳米颗粒可通过抗氧化活性缓解过氧化氢造成的不同程度细胞损伤，表现出良好的肝保护效果，可作为一种高效保肝护肝体系。

聚唾液酸-聚合物缀合物和纳米颗粒

Resumen de: AU2024252577A1

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

一种具有疫苗免疫增强作用的蒲公英多糖PLGA纳米颗粒的制备方法

Nº publicación: CN121243366A 02/01/2026

Solicitante:

河南牧业经济学院

Resumen de: CN121243366A

本发明涉及生物药品制造领域，具体为一种具有疫苗免疫增强作用的蒲公英多糖PLGA纳米颗粒的制备方法，所述蒲公英多糖PLGA纳米颗粒的平均粒度为80‑120 nm，Zeta电势为‑35.5±0.5mV，包封率≥84%，24 h释放率≥83%。本方案制得了包封率≥84%，载药量≥4.5%，24 h释放率≥83%且能够稳定储存的蒲公英多糖PLGA纳米颗粒，能够应用于疫苗药物，具有疫苗免疫增强作用。